DE60025022D1 - Nachweis von hla-g - Google Patents

Nachweis von hla-g

Info

Publication number
DE60025022D1
DE60025022D1 DE60025022T DE60025022T DE60025022D1 DE 60025022 D1 DE60025022 D1 DE 60025022D1 DE 60025022 T DE60025022 T DE 60025022T DE 60025022 T DE60025022 T DE 60025022T DE 60025022 D1 DE60025022 D1 DE 60025022D1
Authority
DE
Germany
Prior art keywords
hla
antibodies
disclosed
detection
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60025022T
Other languages
English (en)
Inventor
Clifford L Librach
Shang-Mian Yie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60025022D1 publication Critical patent/DE60025022D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/906—Fertility tests
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Insulating Materials (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
DE60025022T 1999-09-27 2000-09-27 Nachweis von hla-g Expired - Lifetime DE60025022D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40705699A 1999-09-27 1999-09-27
PCT/CA2000/001116 WO2001023893A2 (en) 1999-09-27 2000-09-27 Detection of hla-g

Publications (1)

Publication Number Publication Date
DE60025022D1 true DE60025022D1 (de) 2006-01-26

Family

ID=23610425

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60025022T Expired - Lifetime DE60025022D1 (de) 1999-09-27 2000-09-27 Nachweis von hla-g

Country Status (7)

Country Link
US (1) US6613538B2 (de)
EP (1) EP1224465B1 (de)
AT (1) ATE313799T1 (de)
AU (1) AU780825B2 (de)
CA (1) CA2386066C (de)
DE (1) DE60025022D1 (de)
WO (1) WO2001023893A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
WO2005022149A1 (en) * 2003-08-28 2005-03-10 Coopersurgical, Inc. Method for determining embryo quality
US20050241013A1 (en) * 2004-04-22 2005-10-27 Geoffrey Sher Unique use of sHLA-G obtained in soluble form from JEG-3 cell line, by purification by PCR, HPLC, or any other techniques, as well as in other forms, as an implantation promoting agent when added to embryo culture and/or to the media in which embryos are transferred to the uterus following in vitro fertilization
EP1994408A4 (de) * 2006-01-27 2009-05-06 Eastern Virginia Med School Proteomische fingerabdrücke menschlicher ivf-embryonen: identifikation von biomarkern mit entwicklungspotential
DE602007004143D1 (de) 2006-04-20 2010-02-25 Northern Sydney And Central Co Verfahren zur Beurteilung der Lebensfähigkeit von Embryos
EP2670868A4 (de) * 2011-01-31 2015-05-06 Esoterix Genetic Lab Llc Verfahren zur anreicherung von mikropartikeln oder nukleinsäuren mittels bindungsmolekülen
EP3274715A4 (de) * 2015-03-27 2018-10-10 University of Southern California Hla-g als neuartiges target der car-t-zell-immuntherapie
ES2904573T3 (es) 2015-03-27 2022-04-05 Univ Southern California Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
CN113045656B (zh) * 2020-07-27 2022-03-08 台州恩泽医疗中心(集团) 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213620A1 (en) * 1995-04-07 1996-10-10 The Regents Of The University Of California Antibodies for the detection of hla-g
CA2321223A1 (en) * 1998-02-25 1999-09-02 National University Of Ireland, Cork Hla linked pre-eclampsia and miscarriage susceptibility gene
EP1131632A2 (de) * 1998-11-16 2001-09-12 Umedik, Inc. Vorrichtung und verfahren zur analyse einer biologischen probe

Also Published As

Publication number Publication date
WO2001023893A3 (en) 2001-05-17
AU780825B2 (en) 2005-04-21
AU7500600A (en) 2001-04-30
CA2386066A1 (en) 2001-04-05
WO2001023893A2 (en) 2001-04-05
US20020015973A1 (en) 2002-02-07
EP1224465B1 (de) 2005-12-21
CA2386066C (en) 2004-12-21
EP1224465A2 (de) 2002-07-24
ATE313799T1 (de) 2006-01-15
US6613538B2 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
PT1190257E (pt) Deteccao precoce dos flavivirus, utilizando a glicoproteina ns1
ATE396264T1 (de) Zytokinrezeptoruntereinheit-proteine aus säugetieren, damit zusammenhängende reagenzien und methoden
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
DK1692181T3 (da) Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin
DE60025022D1 (de) Nachweis von hla-g
DE60232248D1 (de) Schwangerschaftsnachweisverfahren
EP1433792A3 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
BR9709958A (pt) Polipeptídeos capaz de formar estruturas de ligaçãode antígeno com especificidade para os antígenos de rhesus d o dna que os codifica e o processo para sua preparação e uso
WO2001061305A3 (en) Immunoassays detecting or making use of at least two rubber latexallergens
WO2002061436A8 (en) Methods and devices for quantitation of glycated protein
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
CA2308604A1 (en) Antibodies against phosphorylated vasp (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
DE69427484T2 (de) Angiotensin ii rezeptor typ i spezifische monoklonale antikörper und hybridoma
WO2002090989A3 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE229651T1 (de) Rezeptorbindungsassays und reagenziensatz zum nachweis von tsh-rezeptor-autoantikörpern
Fox Measurement of streptococcal antigen synthesis with fluorescent antibody.
Bock et al. Characterization of the D2-cell adhesion molecule
MXPA02011906A (es) Ensayo, equipo y procedimiento a base de esferas no lavables.
ATE490346T1 (de) In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
AU2001295423A1 (en) Indirect method for the quantitative analysis of the binding capacity present in an aqueous protein solution
WO2002078635A3 (en) Estrogen receptor modulators
ATE299739T1 (de) Neurokinin b vorläufer aus menschlicher plazenta
BR0204612C1 (pt) anticorpos monoclonais antinúcleo de hcv

Legal Events

Date Code Title Description
8332 No legal effect for de